Neuroleptic malignant syndrome induced by blonanserin

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 23, Issue 1, 2011, Pages

  Ohoyama, Keiko ^a,b   Tanii, Hisashi ^a,c   Motomura, Eishi ^a   Konishi, Yoshiaki ^a   Nakagawa, Masanori ^a   Matsumoto, Takuya ^a   Shiroyama, Takashi ^a   Okada, Motohiro ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Suisawa Psychiatric Hospital Yokkaichi   (Japan)

^c MIE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLONANSERIN; DIAZEPAM;

ADULT; AUDITORY HALLUCINATION; CASE REPORT; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; INSOMNIA; INTELLECTUAL IMPAIRMENT; LETTER; LEUKOCYTE; MENTAL DEFICIENCY; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PALLIATIVE THERAPY; PERSECUTORY DELUSION; PRIORITY JOURNAL; PULSE RATE; RESTLESSNESS; SIDE EFFECT; SWEATING;

ADULT; FEMALE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; PIPERAZINES; PIPERIDINES;

EID: 80054924370     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.23.1.E13     Document Type: Letter

References (3)

1. 2 antagonist properties. J Pharmacol Exp Ther 1993; 264:158-165
2. Garcia E, Robert M, Peris F, et al: The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, doubleblind, placebo-controlled, multicentre study. CNS Drugs 2009; 23:615-625
3. Viejo LF, Morales V, Punal P, et al: Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand 2003; 107:45-49